Pharma firm Venus Remedies today said it has secured its first patent from Canada for its antibiotic drug ‘Vancoplus’ and will roll out the product in that country in the next two years.
"We are enthusiastic over the receival of this Canadian patent for Vancoplus. It will prove to be a fertile ground for the success of this product not just commercially but also in terms of catering to the constantly rising Methicillin Resistant Staphylococcus Aureus (MRSA) infection rates in Canada," Manu Chaudhary, Joint MD, Venus Remedies, said in a statement today.
The patent has been granted by the Canadian patent office and is valid up to May 2027, the company statement said.
As per a research report published by Canadian Antimicrobial Resistance Alliance (CARA), MRSA cases have increased significantly from 19.5% in 2007 to 38.1% in 2010.
The drug will provide treatment for typhoid, pneumonia, urinary tract infection, skin infection and other diseases.
"As the Canadian pharmaceutical market is the third fastest growing market globally, it shows great growth potential for R&D players in the industry to create better drugs to curb such diseases," said Chaudhary.
Apart from Canada, the patent for this product has already been granted in US, South Africa, New Zealand, Ukraine and Australia, the company said.
